Insiders Trades

★ Sign in to follow

KA

Kabeer Aziz

Board Director

Director

US·SEC (Form 4)

AN2 Therapeutics, Inc.

Cumul. flow

Total declarations

35

Company

1

▲ Purchases (1 ops.)

€2.3M

▼ Sales (20 ops.)

€3.7M

Latest filing published 13 Oct 2026 for AN2 Therapeutics, Inc..

Filing timeline

BuySale

Kabeer Aziz

Insider track record

Disclosed buys

1

Disclosed sells

20

Signal history

Closed purchases

Market purchases

1

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

AN2 Therapeutics, Inc. 1 purchase · last 31 Mar 2022

Kabeer Aziz: trading record in brief

All filings by Kabeer Aziz on record concern AN2 Therapeutics, Inc., in the capacity of board member. In total, 35 filings cover trades dated from 29 March 2022 to 12 October 2026.

Market trades split into 1 purchase (€2.3M) and 20 sales (€3.7M). Taken together, the sales exceed the purchases by €1.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 8 share grants.

The latest filing, published on 13 October 2026, reports a share grant in AN2 Therapeutics, Inc. The clock since the last published purchase (31 March 2022) now reads 1,667 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Kabeer Aziz

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

AN2 Therapeutics, Inc. (US)

Declarations16 total

◆

DirectorExecutives12 Oct 2026AN2 Therapeutics, Inc.

0SEC

2,465 shares0Common StockSEC:0001193125-26-420639:0

◆

DirectorExecutives10 Jul 2026AN2 Therapeutics, Inc.

0SEC

2,852 shares0Common StockSEC:0001193125-26-301167:0

◆

DirectorExecutives10 Apr 2026AN2 Therapeutics, Inc.

0SEC

3,775 shares0Common StockSEC:0001193125-26-151632:0

◆

DirectorExecutives12 Jan 2026AN2 Therapeutics, Inc.

0SEC

11,560 shares0Common StockSEC:0001193125-26-013041:0

◆

DirectorExecutives10 Oct 2025AN2 Therapeutics, Inc.

0SEC

10,367 shares0Common StockSEC:0001193125-25-238983:0

◆

DirectorExecutives10 Jul 2025AN2 Therapeutics, Inc.

0SEC

11,875 shares0Common StockSEC:0000950170-25-095408:0

◆

DirectorExecutives10 Apr 2025AN2 Therapeutics, Inc.

0SEC

9,705 shares0Common StockSEC:0000950170-25-053367:0

◆

DirectorExecutives19 Dec 2024AN2 Therapeutics, Inc.

0SEC

8,972 shares0Common StockSEC:0000950170-24-139800:0

▼

DirectorExecutives16 Jan 2024AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

312,573 USD30SEC

15,907 shares@ US$19.659.2% of flowCommon StockSEC:0000950170-24-005515:1

▼

DirectorExecutives16 Jan 2024AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

2M USD33SEC

84,093 shares@ US$19.6542.1% of flowCommon StockSEC:0000950170-24-005515:0

▼

DirectorExecutives14 Nov 2023AN2 Therapeutics, Inc.

4,651 USD23SEC

288 shares@ US$16.150.1% of flowCommon StockSEC:0000950170-23-064609:1

▼

DirectorExecutives14 Nov 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

24,574 USD23SEC

1,522 shares@ US$16.1460.6% of flowCommon StockSEC:0000950170-23-064609:0

▼

DirectorExecutives29 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

1M USD27SEC

83,337 shares@ US$16.2835.8% of flowCommon StockSEC:0000950170-23-051733:0

▼

DirectorExecutives29 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

256,638 USD24SEC

15,764 shares@ US$16.286.8% of flowCommon StockSEC:0000950170-23-051733:1

▼

DirectorExecutives2 Oct 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

76,654 USD23SEC

4,770 shares@ US$16.072.0% of flowCommon StockSEC:0000950170-23-051733:2

▼

DirectorExecutives2 Oct 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

14,495 USD23SEC

902 shares@ US$16.070.4% of flowCommon StockSEC:0000950170-23-051733:3

▼

DirectorExecutives27 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

2,153 USD23SEC

134 shares@ US$16.070.1% of flowCommon StockSEC:0000950170-23-050851:1

▼

DirectorExecutives28 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

115,348 USD23SEC

7,160 shares@ US$16.113.5% of flowCommon StockSEC:0000950170-23-050851:2

▼

DirectorExecutives28 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

21,845 USD23SEC

1,356 shares@ US$16.110.7% of flowCommon StockSEC:0000950170-23-050851:3

▼

DirectorExecutives27 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

11,361 USD23SEC

707 shares@ US$16.070.3% of flowCommon StockSEC:0000950170-23-050851:0

▼

DirectorExecutives13 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

1,024 USD23SEC

64 shares@ US$16.000.0% of flowCommon StockSEC:0000950170-23-048436:1

▼

DirectorExecutives13 Sept 2023AN2 Therapeutics, Inc.

5,376 USD23SEC

336 shares@ US$16.000.1% of flowCommon StockSEC:0000950170-23-048436:0

▼

DirectorExecutives6 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

9,580 USD23SEC

598 shares@ US$16.020.3% of flowCommon StockSEC:0000950170-23-047311:1

▼

DirectorExecutives7 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

45,598 USD23SEC

2,841 shares@ US$16.051.4% of flowCommon StockSEC:0000950170-23-047311:2

▼

DirectorExecutives7 Sept 2023AN2 Therapeutics, Inc.

Same trade as the filing by Adjuvant Global Health Technology Fund, L.P., counted once

8,619 USD23SEC

537 shares@ US$16.050.3% of flowCommon StockSEC:0000950170-23-047311:3

25 of 16 declarations